Features of the use of genetic engineering biological drugs in the treatment of patients with Crohn’s disease

Nina A. Fadeeva; Фадеева Нина Александровна; O. V. Knyazev; Князев О. В.; D. S. Bordin; Бордин Д. С.; K. A. Nikolskaya; Никольская К. А.; S. M. Chudnykh; Чудных С. М.; N. A. Dashkina; Дашкина Н. А.; G. B. Artykova; Артыкова Г. Б.; E. I. Aliev; Алиев Э. И.

doi:10.18565/pharmateca.2023.14.44-48

Features of the use of genetic engineering biological drugs in the treatment of patients with Crohn’s disease

Authors: Fadeeva N.A.¹^,2, Knyazev O.V.¹^,3, Bordin D.S.¹^,4^,5, Nikolskaya K.A.¹^,2, Chudnykh S.M.¹^,5, Dashkina N.A.¹^,2, Artykova G.B.¹^,2, Aliev E.I.¹^,2
Affiliations:
1. Loginov Moscow Clinical Scientific and Practical Center
2. Research Institute of Healthcare Organization and Medical Management of the Moscow Healthcare Department
3. Ryzhikh National Medical Research Center of Coloproctology
4. Tver State Medical University
5. A.I. Yevdokimov Moscow State University of Medicine and Dentistry
Issue: Vol 30, No 14 (2023)
Pages: 44-48
Section: Gastroenterology/hepatology
URL: https://journals.eco-vector.com/2073-4034/article/view/626216
DOI: https://doi.org/10.18565/pharmateca.2023.14.44-48
ID: 626216

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription or Fee Access

Abstract
Full Text
About the authors
References
Supplementary files
Statistics

Abstract

Background. Genetically engineered biological drugs (GEBDs) have now become the drugs of choice for the treatment of inflammatory bowel diseases (IBD) and have been successfully used since their discovery. This is due to their ability to effectively influence both the IBD pathogenetic mechanisms and symptoms. For the effective and safe use of biological drugs, it is necessary to comply with the indications and rules for their use, and irrational prescription and use of biological drugs can lead to side effects.

Description of a series of clinical cases. The article presents a clinical case of a complicated course of Crohn’s disease (CD) in a young patient, reflects the features of diagnosis and course, and treatment tactics for CD. The problem of loss of response to biological therapy and management features are revealed.

Conclusion. The ability to provide timely and high-tech medical care using modern physical therapy makes it possible to avoid the development of surgical complications for a long time and slow down the progression of IBD.

Keywords

Crohn’s disease, inflammatory bowel disease, ustekinumab, biological therapy

Full Text

About the authors

Nina A. Fadeeva

Loginov Moscow Clinical Scientific and Practical Center; Research Institute of Healthcare Organization and Medical Management of the Moscow Healthcare Department

Author for correspondence.
Email: n.fadeeva@mknc.ru
ORCID iD: 0000-0002-0524-2514

Associate Professor, Department of Gastroenterology

Russian Federation, Moscow; Moscow

References

Хатьков И.Е., Парфенов А.И., Князев О.В. и др. Воспалительные заболевания кишечника в практике терапевта и хирурга. М.: Вита-ПРЕСС, 2017. [Khatkov I.E., Parfenov A.I., Knyazev O.V. and others. Inflammatory bowel diseases in the practice of therapists and surgeons. M.: Vita-PRESS, 2017. (In Russ.)].
Satsangi J., Silverberg M.S., Vermeire S., Colombel J.F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749–53.
Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95.
Sandborn W.J., Feagan B.G., Rutgeerts P., et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–21.
Hindryckx P., Vande Casteele N., Novak G., et al. The Expanding Therapeutic Armamentarium for Inflammatory bowel disease: how to choose the right drug[s] for our patients? J Crohn’s Colitis. 2018;12(1):105–19.
Armuzzi A., Ardizzone S., Biancone L., et al. Digestive and liver disease. Dig Liver Dis. 2018;50(7):653–60.
Giulia R., Bindia J. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Translat Gastroenterol. 2016;7:e135. doi: 10.1038/ctg.2015.63.
Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–49.
Hanauer S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–33.
Colombel J.-F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.
Nicholas A.,Graham A. Heap et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019(5):341–53. doi: 10.1016/S2468-1253(19)30012-3.
Geert R., Panaccione R., Higgins P.D., et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol.2011;106(2): 199–212.
STELARA (ustekinumab) injection, for subcutaneous or intravenous use. Prescribing Information and Summary of Product Characteristics. Janssen Biotech, Inc., 2018.
Feagan B.G., Sandborn W.J., Gasink C., et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946–60.
Sandborn W.J., Rutgeerts P., Gasink C., et al. Longterm efficacy and safety of ustekinumab for Crohn’s disease through the second year of therapy. Aliment Pharmacol Ther. 2018; 4(1):65–77.
Li K., Chan D., Pollack P., et al. Efficacy of ustekinumab for induction and maintenance of histological healing in patients with Crohn’s disease. Gastroenterology. 2017; 152(1):595.
Князев О.В., Никольская К.А., Фадеева Н.А. и др. Эффективность и безопасность устекинумаба у пациентов с воспалительными заболеваниями кишечника в реальной клинической практике. Эффективная фармакотерапия. 2021;17(39):40–7. [Knyazev O.V., Nikolskaya K.A., Fadeeva N.A. et al. Efficacy and safety of ustekinumab in patients with inflammatory bowel diseases in real clinical practice. Effective pharmacotherapy. 2021;17(39):40–7. (In Russ.)].